Accordingly, it has been recently demonstrated by flow-cytometry that DNA methyltrasnferase inhibitors (DNMTi), as azacytidine (AZA) and decitabine (DEC), increase CD38 expression on a panel of human MM cell lines, without affecting cell viability [58]. This evidence concerns the gene CD38 and Miyoshi myopathy.